Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Houston, Texas, focused on developing proprietary treatments that target inflammation and enhance the function of regulatory T cells (Tregs). Tregs play a critical role in immune regulation, and their dysfunction is implicated in a range of diseases including neurodegenerative, metabolic, and autoimmune conditions. Coya's approach leverages multiple therapeutic modalities, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, to restore immune balance and potentially modify disease progression.

Coya's lead product candidate, COYA 302, is a dual-mechanism biologic combination therapy designed to enhance Treg function and suppress proinflammatory cell function. The company is currently advancing COYA 302 through clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Parkinson's Disease (PD). Coya believes that this combination therapy approach has the potential to overcome the complexity of inflammatory pathways that characterize these diseases and offer disease-modifying benefits to patients.

Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). They are working to create multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases, with the goal of restoring the anti-inflammatory and immunomodulatory functions of Tregs, ultimately impacting the lives of patients suffering from these conditions.

Coya Therapeutics promotes a culture that values scientific innovation and collaboration. They prioritize developing proprietary treatments that address unmet medical needs, particularly in neurodegenerative, autoimmune, and metabolic diseases. The company's strong commitment to research and development is evident in their partnerships with leading institutions like Houston Methodist Hospital and their focus on multiple therapeutic modalities. This commitment to innovation is fueled by a collaborative environment, as evidenced by their diverse and experienced leadership team, scientific advisory board, and dedication to attracting and retaining key scientific personnel.